ConductScience.org, home

Paper22871663

Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Galanis E and 16 others. Mol Ther, 2012. Cited by 132 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Papers, record 22871663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22871663

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
PubMed
Journal
Mol Ther
PubMed
Year
2012
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
132
iCite
Relative citation ratio, by iCite
3.42
iCite
Revised in PubMed
2025-05-29
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Galanis EEvanthia
2Markovic SNSvetomir N
3Suman VJVera J
4Nuovo GJGerard J
5Vile RGRichard G
6Kottke TJTimothy J
7Nevala WKWendy K
8Thompson MAMichael A
9Lewis JEJean E
10Rumilla KMKandelaria M
11Roulstone VVictoria
12Harrington KKevin
13Linette GPGerald P
14Maples WJWilliam J
15Coffey MMatt
16Zwiebel JJames
17Kendra KKari

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Mammalian orthoreovirus 3Major topic
MelanomaMajor topic
Oncolytic VirotherapyMajor topic
Administration, Intravenous
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf
Proto-Oncogene Proteins p21(ras)
Virus Replication
Young Adult
ras Proteins

Source PubMed

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
N01CM 62205-5NCI NIH HHSUnited StatesN01CM622055PubMedNIH RePORTER
N01 CM062205NCI NIH HHSUnited StatesN01CM062205PubMedNIH RePORTER
R01 CA107082NCI NIH HHSUnited StatesR01CA107082PubMed and NIHNIH RePORTER
R01 CA154348NCI NIH HHSUnited StatesR01CA154348PubMed and NIHNIH RePORTER
R01 CA130878NCI NIH HHSUnited StatesR01CA130878PubMed and NIHNIH RePORTER

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120,587,792Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.J Natl Cancer Inst2010https://conductscience.org/library/papers/20587792PubMed
218,401,435Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.Gene Ther2008https://conductscience.org/library/papers/18401435PubMed
318,981,012A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.Clin Cancer Res2008https://conductscience.org/library/papers/18981012PubMed
419,572,105Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.Invest New Drugs2010https://conductscience.org/library/papers/19572105PubMed
511,007,773Transcriptional activities of reovirus RNA polymerase in recoated cores. Initiation and elongation are regulated by separate mechanisms.J Biol Chem2000https://conductscience.org/library/papers/11007773PubMed
69,628,872The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.EMBO J1998https://conductscience.org/library/papers/9628872PubMed
72,982,027Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease.J Virol1985https://conductscience.org/library/papers/2982027PubMed
84,371,523The reovirus murine models.Prog Med Virol1974https://conductscience.org/library/papers/4371523PubMed
919,773,377Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.Clin Cancer Res2009https://conductscience.org/library/papers/19773377PubMed
1019,594,950Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.Mol Cancer2009https://conductscience.org/library/papers/19594950PubMed
1119,884,534Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.J Clin Oncol2009https://conductscience.org/library/papers/19884534PubMed
1218,172,278Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.Clin Cancer Res2008https://conductscience.org/library/papers/18172278PubMed
1321,886,163Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature2011https://conductscience.org/library/papers/21886163PubMed
1421,107,323Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.Nature2010https://conductscience.org/library/papers/21107323PubMed
1520,801,221The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.Methods2010https://conductscience.org/library/papers/20801221PubMed
1621,106,728A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.Clin Cancer Res2011https://conductscience.org/library/papers/21106728PubMed
1719,509,134Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.Clin Cancer Res2009https://conductscience.org/library/papers/19509134PubMed
1811,932,414Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules.J Virol2002https://conductscience.org/library/papers/11932414PubMed
1921,639,808Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med2011https://conductscience.org/library/papers/21639808PubMed
2020,528,232OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.Future Oncol2010https://conductscience.org/library/papers/20528232PubMed

See all 35 references

Cited by95

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.

PMIDTitleJournalYearIn PapersSource
41,817,273Enhanced sialic acid engagement at physiological temperatures by reovirus σ1 mutants facilitates infection of breast cancer cells with low levels of high-affinity receptors.J Virol2026https://conductscience.org/library/papers/41817273PubMed
41,792,783Reovirus resistance in tumors mediated by elevated ISG expression: overcoming therapeutic resistance via JAK/STAT pathway modulation.Virol J2026https://conductscience.org/library/papers/41792783PubMed
41,696,944Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma.Int J Cancer2026https://conductscience.org/library/papers/41696944PubMed
41,315,764Innate immunity in tumour immunoediting and immunosurveillance.EMBO J2026https://conductscience.org/library/papers/41315764PubMed
41,150,456Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis.Vaccines (Basel)2025https://conductscience.org/library/papers/41150456PubMed
40,991,899A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses.Cancer Control2025https://conductscience.org/library/papers/40991899PubMed
40,734,810Oncolytic viral therapy as a novel potential solution for treatment of pancreatic cancer.Gastroenterol Hepatol Bed Bench2025https://conductscience.org/library/papers/40734810PubMed
40,539,780Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.J Virol2025https://conductscience.org/library/papers/40539780PubMed
40,480,657Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors.J Immunother Cancer2025https://conductscience.org/library/papers/40480657PubMed
40,365,251Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?Skin Health Dis2025https://conductscience.org/library/papers/40365251PubMed
39,772,250Human Melanoma and Glioblastoma Cells Express Cathepsins Supporting Reovirus Moscow Strain Infection.Viruses2024https://conductscience.org/library/papers/39772250PubMed
39,013,849Exploring treatment options in cancer: Tumor treatment strategies.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39013849PubMed
38,771,042Sequence polymorphisms in the reovirus σ1 attachment protein modulate encapsidation efficiency and replication in mice.J Virol2024https://conductscience.org/library/papers/38771042PubMed
38,194,598Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.Cancer Immunol Res2024https://conductscience.org/library/papers/38194598PubMed
38,033,400Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment.Mol Ther Oncolytics2023https://conductscience.org/library/papers/38033400PubMed
37,919,738The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis.Virol J2023https://conductscience.org/library/papers/37919738PubMed
37,686,579Anticancer Activity of Measles-Mumps-Rubella MMR Vaccine Viruses against Glioblastoma.Cancers (Basel)2023https://conductscience.org/library/papers/37686579PubMed
37,629,523New Treatment Horizons in Uveal and Cutaneous Melanoma.Life (Basel)2023https://conductscience.org/library/papers/37629523PubMed
37,515,162Modulation of Reoviral Cytolysis (II): Cellular Stemness.Viruses2023https://conductscience.org/library/papers/37515162PubMed
37,458,862Oncolytic viruses against cancer, promising or delusion?Med Oncol2023https://conductscience.org/library/papers/37458862PubMed

See all 95 cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
KRAS3,845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22871663

GET https://conductscience.org/api/papers/v1/22871663/references?page=2